ПЕРСПЕКТИВЫ ИСПОЛЬЗОВАНИЯ БАКТЕРИАЛЬНЫХ ЛИПОПОЛИСАХАРИДОВ В ГЕПАТОЛОГИИ


  • С. А. Черняк УО "Гродненский государственный медицинский университет", Гродно, Беларусь http://orcid.org/0000-0001-6558-5044
Ключевые слова: бактериальные липополисахариды, иммуномодуляторы, гепатиты, фиброз печени

Аннотация

Введение. Исследование новых свойств бактериальных липополисахаридов (БЛПС), не связанных с их интоксикационной активностью, представляет большой интерес. Цель исследования – описание механизмов действия и оценка эффективности применения БЛПС. Материал и методы. Проведен анализ 32 литературных источников, опубликованных в период с 1962 по 2020 гг. Результаты. Установлено, что помимо иммуномодулирующего эффекта, БЛПС способны оказывать противовоспалительное, противоопухолевое, радиопротекторное действие, стимулировать регенерацию тканей. Широкий спектр терапевтической активности установлен при заболеваниях гепатобилиарной системы, что нашло подтверждение в ходе экспериментальных и клинических исследований. Назначение БЛПС приводит к укорочению манифестной стадии острых гепатитов, способствует быстрейшей норма- лизации функциональных печёночных проб и восстановлению морфологических изменений в печени. Заключение. Наличие у БЛПС гепатопротективных и антифиброзных свойств дает основания рекомендовать их врачам-гепатологам для более широкого применения в лечебной практике.

Литература

Brade H. Endotoxin in Health and Disease. New York;Basel: Marcel Dekker; 1999. 962 p.

Belova ZN, Budnitskaya PZ. Himicheskij sostav lipoidnojchasti pirogenala R i znachenie lipoida A v pirogennoj aktivnosti preparata [Chemical composition of the lipoid partof pyrogenal P and the value of lipoid A in the pyrogenicactivity of the drug]. Bjulleten jeksperimentalnoj biologii imediciny [Bulletin of Experimental Biology and Medicine].1970;70(9):36-39. (Russian).

Lipopolisaharid [Lipopolysaccharide][Internet]. Available from: https://clck.ru/9aZZS (Russian).

Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H,Ikeda H. Molecular mechanisms of macrophage activationand deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther. 2003;100(2):171-194. doi:10.1016/j.pharmthera.2003.08.003.

Marshall JC. Lipopolysaccharide:an endotoxin or an exogenoushormone. Clin Infec Dis. 2005;41(7):470-480.

Ermoleva ZV, Vajsberg GE. Stimuljacija nespecificheskoj rezistentnosti organizma i bakterialnye polisaharidy.Moscow: Medicina; 1976. 182 p. (Russian).

Vasilyev VS. Lipopolisaharidy v processe immunogeneza:tendencii nauchnogo poiska i itogi izuchenija v uslovijahinfekcionno j patologii [Lipopolysaccharides during immunogenesis: scientific search trends and results in the studyof infectious diseases]. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta [Journal of the GrodnoState Medical University]. 2014;1(45):98-103. (Russian).

Maslakov DA, Ejsmont KA, Maximovich NE. Sovremennyepredstavlenija o biologicheskom dejstvii preparatov polisaharidnoj prirody [Current notions on polysaccharide nature,spreparations, biological effect]. Medicinskie Novosti [Medicalnews]. 2000;5(59):19-22. (Russian).

Kutina SN. Rol funkcionalnogo sostojanija sistemy mononuklearnyh fagocitov v razvitii CC1-4-cirroza i involjuciifibroznoj transformacii pecheni [masters thesis]. Irkutsk(Russia): Nauchnyj centr klinicheskoj i jeksperimentalnojmediciny Sibirskogo otdelenija Rossijskoj Akademii medicinskih nauk; 2000. 29 p. (Russian).

Botchenko LV, Redechkina CI. Kliniko-immunologicheskiepokazateli jeffektivnosti prodigiozana pri virusnom gepatiteu detej. In: Poljakov EM, ed. Virusy i virusnye zabolevanija. Sbornik statej. Kiev: Zdorovja; 1985. Iss. 13; p. 80-83 (Russian).

Prodigiozan: instrukcija po primeneniju, sostav i svojstva [Internet]. Available from: https://ru-transferfactor.ru/prodigiozan (Russian).

Budnickaja PZ. Vydelenie, himicheskaja harakteristika inekotorye biologicheskie svojstva preparata pirogenala[masters thesis]. Moscow (Russia): NF Gamaleya FederalResearch Center for Epidemiology & Microbiology; 1963. 14p. (Russian).

Budnickaja PZ. K voprosu o himicheskoj prirode pirogennogo veshhestva pirogenala [On the chemical nature of thepyrogenic substance – pyrogenal]. Bjulleten jeksperimentalnoj biologii i mediciny [Bulletin of Experimental Biology andMedicine]. 1962;3(3):53-56. (Russian).

Avramenko MM. Vlijanie vysokomolekuljarnyh soedinenijtipa lipopolisaharidov na funkcionalnoe sostojanie pecheni na modeli CCl4-gepatoza u krys. In: Zlatkina AR, ed.Patologija pecheni i zhelchnyh putej. Trudy. Moscow: TheState Budgetary Healthcare Institution of Moscow Area Moscows regional research clinical institute named after MFVladimirskiy; 1971. p. 122-125. (Russian).

Avramenko MM, Gladyshev BN, Veinova MK, AfanasevaEM. Vlijanie pirogenala i gljukomannana na soderzhaniepeptidov i nukleotidpeptidov v tkani pecheni i belki syvorotkikrovi pri CCl4-gepatoze u krys [Effect of pyrogenal and glucomannan on the content of liver peptides and nucleopeptides and of blood serum proteins under CCl4-hepatosis inrats]. Voprosy medicinskoj himii [Medical chemistry issues].1972;17(6):627-630. (Russian).

Vakulin GM. Morfologicheskie kriterii snizhenija pronicaemosti i trofiki cirroticheski izmenennoj pecheni krys i ihpovyshenija pod vlijaniem pirogenala i piridoksalfosfata(morfometrija trasmissionnaja i rastrovaja jelektronnajamikroskopija) [Morphological criteria of the loss of permeability and trophics of cirrhotically changed liver of rats andincrease thereof under the effect of pyrogenal and pyridoxalphospate (morphometry, transmission and scanningelectron microscop]. Bjulleten jeksperimentalnoj biologii imediciny [Bulletin of Experimental Biology and Medicine].1993;116(12):645-650. (Russian).

Akopova VL. Funkcionalnoe sostojanie pecheni u bolnyhhronicheskim gepatitom i cirrozom pecheni v processelechenija pirogenalom. In: Vasilenko VH, executive ed.Problemy diagnostiki i pojetapnogo lechenija gastrojenterologicheskih bolnyh. Materialy Vsesojuznogo plenumapravlenija obshhestva; 1974 Sept 6-8; Essentuki. Essentuki;1974. p. 147-148. (Russian).

Saveleva LA. Dinamika aktivnosti izofermentov malat- i laktatdegidrogenazy pri lechenii pirogenalom cirroza pecheni udetej [Dynamics of the activity of isoenzymes of malic andlactic-dehydrogenases in pyrogenal treatment of cirrhosis ofthe liver in children]. Voprosy ohrany materinstva i detstva.1969;14(10):67-70. (Russian).

Saveleva LA, Drozdova GA. Fermentativnyj spektrsyvorotki krovi pri lechenii pirogenalom cirroza pecheniu detej. In: Samson EI, executive ed. Voprosy profilaktiki,diagnostiki i lechenija zabolevanij organov pishhevarenija.Tezisy dokladov respublikanskoj nauchno-prakticheskoj konferencii vrachej-gastrojenterologov; 1970 Sept 9;Chernivtsi. Chernivtsi; 1970. p. 234-235. (Russian).

Petrova TR, Ponomareva EP. Vlijanie pirogenala navnutrikletochnyj metabolizm i fagocitarnuju aktivnostlejkocitov u bolnyh hronicheskimi zabolevanijami pecheni[Effect of pyrogenal on intracellular metabolism andphagocytic activity of leukocytes in patients with chronic diseases of the liver]. Klinicheskaja medicina [Clinicalmedicine]. 1975;53(8):34-39. (Russian).

Zejgermaher GA. Rezultaty primenenija pirogenala v kompleksnom lechenii virusnogo gepatita (bolezni Botkina)[masters thesis]. Donetsk (Ukraine): Maxim Gorky DonetskNational Medical University; 1972. 20 p. (Russian).

Polomeev JuG. Kliniko-jepidemiologicheskaja harakteristika virusnogo gepatita A u voennosluzhashhih v uslovijahboevyh dejstvij [masters thesis]. Tomsk (Russia): SiberianState Medical University; 2004. 20 p. (Russian).

Gamaleya NB, Shostak OA, Makarova NYe, Uliyanova LI, alkogolizmom, oslozhnennym i ne oslozhnennym virusnymigepatitami V i S, i vlijanie na nih immunomoduljatora pirogenala [Immunity indices in patients with alcoholism, complicated and not complicated with virus hepatitises B andC, and the immunomodulator effect]. Voprosy narkolog

Surovikina MS, Saveleva LA, Tarasova LV, Domnikov AI, Surovikin VV. Pokazateli kininogeneza kak kriterij ocenki jeffektivnosti lechenija zabolevanij gepatobiliarnoj sistemy u detej. Almanah klinicheskoj mediciny [Almanac of Clinical Medicine]. 2002;5:236-243. (Russian).

Hochava AI. Nekotorye patogeneticheskie aspekty pirogenaloterapii pri virusnom gepatite. In: Getman II, executive ed. Voprosy jeksperimentalnoj i klinicheskoj gepatologii. Materialy respublikanskoj nauchnoj konferencii; 1976 Oct 21-22; Ternopil. Ternopil: Ternopil Medical Institute; 1976. p. 340-341. (Russian).

Boguckij MI. Vlijanie pirogenala na klinicheskoe techenie bolezni i funkcionalnoe sostojanie kory nadpochechnikov pri virusnom gepatite [masters thesis]. Kujbyshev (Russia): Samara State Medical University; 1978. 22 p. (Russian).

Vasilev VS. Kliniko-patogeneticheskoe obosnovanie primenenija pirogenala i prednizolona v kompleksnoj terapii virusnogo gepatita [masters thesis]. Leningrad (Russia): SM Kirov Military Medical Academy; 1980. 473 p. (Russian).

Tsyrkunov VM, Vasilyeva AN, Vasilyev VS, inventors; Grodno State Medical Institute, assignee. Sposob opredelenija individualnoj chuvstvitelnosti k pirogenaloterapii [Method for determining individual sensitivity to pyrogenal therapy]. RU patent 2009497. 1994 Mar 15. (Russian).

Tsyrkunov VM. Harakteristika processa degranuljacii bazofilnyh granulocitov krovi pri vvedenii pirogenala v jeksperimente. In: Krasilnikov AP, executive ed. Voprosy immunologii. Tezisy dokladov Pervoj respublikanskoj immunologicheskoj konferencii; 1982 Nov 25-26; Vitebsk. Vitebsk; 1982. p. 53-54. (Russian).

Chernyak SA. Kliniko-morfologicheskaja harakteristika i antifibroznaja terapija hronicheskogo gepatita C [Clinical and morphological characteristics and antifibrotic therapy of chronic hepatitis C] [masters thesis]. Grodno (Belarus): Grodno State Medical University, Belarusian State Medical University; 2020. 132 p. (Russian).

Pirogenal [Pyrogenal] [Internet]. Available from: http://www. rlsnet.ru/tn_index_id_4968.htm (Russian).

Shvarc JaSh. Reaktivnost makrofagalnoj sistemy pri fibroplasticheskih processah vospalitelnogo geneza: ocenka, mehanizmy reguljacii i patogeneticheskoe znachenie [masters thesis]. Novosibirsk (Russia): The Institute of Internal and Preventive Medicine Novosibirsk; 2010.


Просмотров аннотации: 82
Загрузок PDF: 37
Опубликован
2021-01-13